Gastroenteromema clinically urgently needed drugs will become Hainan's first special batch of take-away drugs.

Guide: Boao Super Hospital, Chengmei Medical and Reding Pharmaceuticals, have introduced the innovative drug Riptinib to patients in urgent need in China.
with the official launch of the General Plan for the Construction of Hainan Free Trade Port in June this year, the global innovation therapy has further broken through the policy of first use in Hainan.
July 28, "Hainan free trade port Boao Lecity, the first special approval to take off the drug and gastrointestinal mesoma clinical urgent drug project launch meeting" held in Haikou.
Gu Gang, Director of Boao Lecheng International Medical Tourism Advance Zone Administration, Secretary of the Party Committee of Hainan Province Drug Administration, Director Jia Ning, Deputy Director of Boao Lecheng International Medical Tourism Advance Zone Administration Liu Zhefeng, Chairman of first Investment Group, Chairman of Hainan Cancer Hospital Jiang Huicheng, Executive Vice President of Boao Super Hospital Fang Hua, and then attended the launch meeting by Liang Yi, Chief Commercial Officer of Boao Pharmaceuticals, President of Greater China.
with the support of the new policy, Boao Super Hospital, Chengmei Medical and Reding Pharmaceuticals have collaborated to introduce Riptinib, an innovative drug for patients in urgent need in China, which will also be the first clinically urgently needed drug used in hainan Free Trade Port after the launch of the general plan;
gastrointestinal interstitial tumor (GIST) is the second most common incidence of gastrointestinal cancer and colorectal cancer, with about 30,000 new diagnoses and an estimated 100,000 patients with gastrointestinal intercomma under treatment in China each year, and malignant gastrointestinal mesocardyomas are considered one of the most difficult to treat tumors.
the first step in the special approval, Ruptinib is the world's first innovative drug for the treatment of four-line gastrointestinal interstitial omas, changing the plight of patients without medication after the progress of third-line treatment.
, after the world's first approval in May this year, entered the First District of Hainan Lecheng in just two months to benefit domestic patients, is the first Chinese and global patients to use a new drug, which also means that thanks to Hainan's free trade port policy, China has been increasingly in line with the "international pace" of innovative drugs. "Boao Lecheng International Medical Tourism Leading Zone, as China's only 'medical special zone', has benefited Hainan's New Deal on Free Trade, further accelerating the international listing of innovative therapies that have not yet been approved in China to benefit domestic patients at a faster rate," said Gu Gang, Director of the International Medical Tourism Leading Area Administration in Boao City,
.
is pleased to be working together to introduce the latest drug, Riptinib, to patients.
advance zone will continue to use these policies to speed up the construction of new highlands in the medical field, and contribute to the construction of Hainan's free trade port.
"